Moderna stock falls after cancer vaccine data leaked ahead of embargo lift
1 independent sourcefirst seen published latency 18 min
Moderna’s stock declined after data for its cancer vaccine circulated before the scheduled embargo lift, according to MarketWatch. The vaccine met its trial targets, but the premature disclosure of results rattled investors.
Sources: MarketWatch
This article is for information only and is not financial advice.
What the market did
Price reactionnot recorded
Independent outlets1
Reports per hour0.00
Noveltyfollow-up1 outlet(s), 97 min spread
Each figure is this site’s own reading, with what it was measured against. A blank is a reading nobody took, not a zero. The before-the-headline window prints the rate a RANDOM hour clears the same bar, because a hit rate without its null is not a finding.
Tags: Moderna, oncology, clinical_trials
